Androgen deprivation therapy for prostate cancer

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges C. Studies on prostate cancer. I. The effects of castration, of estrogen and of androgen injection on serum phospatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7
   Google Scholar
• Maatman TJ, Gupta MK, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985;133(4):620-1
   PubMed Web of Science ®Google Scholar
• Vacurg, Group Tvacur. Carcinoma of the prostate: Treatment comparisons. J Urol 1967;98:516-22
   Google Scholar
• Vacurg, Group Tvacur. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-7
   PubMedGoogle Scholar
• Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32(5):1126-30
   PubMed Web of Science ®Google Scholar
• Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001;19(1):72-80
   PubMed Web of Science ®Google Scholar
• Blackard CE, Doe RP, Mellinger GT, Byar DP. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970;26(2):249-56
   PubMed Web of Science ®Google Scholar
• Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;(7):165-70
   Google Scholar
• Robinson MR, Smith PH, Richards B, et al. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group Phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995;28(4):273-83
   PubMedGoogle Scholar
• Bishop M. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br J Urol 1996;78:921-8
   PubMedGoogle Scholar
• Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD. Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 1973;45(6):668-77
   PubMedGoogle Scholar
• Orlando M, Chacon M, Salum G, Chacon DR. Low-dose continuous oral fosfestrol is highly active in ‘hormone-refractory’ prostate cancer. Ann Oncol 2000;11(2):177-81
   PubMedGoogle Scholar
• Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58(2 Suppl 1):108-13
   PubMed Web of Science ®Google Scholar
• Klotz L, McNeill I, Fleshner N. A Phase I – II trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161(1):169-72
   PubMedGoogle Scholar
• Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22(14):2927-41
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61(4):332-53
   PubMed Web of Science ®Google Scholar
• Labrie F, Belanger A, Susan L, et al. History of LHRH agonist and combination therapy in prostate cancer. Endocr Relat Cancer 1996;3:243-78
   Web of Science ®Google Scholar
• Denis L. European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976 – 1996. Urology 1998;51(5A Suppl):50-7
   PubMedGoogle Scholar
• Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77
   PubMed Web of Science ®Google Scholar
• Tunn UW, Bargelloni U, Cosciani S, et al. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int 1998;60(Suppl 1):9-16; discussion 16-7
   PubMed Web of Science ®Google Scholar
• Dondi D, Limonta P, Moretti RM, et al. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54(15):4091-5
   PubMed Web of Science ®Google Scholar
• Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58(2 Suppl 1):5-9
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987;138(4):804-6
   PubMed Web of Science ®Google Scholar
• Stege R. Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl 2000;10:38-42
   PubMedGoogle Scholar
• Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(10):2171-9
   PubMed Web of Science ®Google Scholar
• Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000;5(2):162-8
   PubMedGoogle Scholar
• Stricker HJ. Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001;58(2 Suppl 1):24-7
   PubMedGoogle Scholar
• Mcleod D, Zinner N, Tomera K, et al. A Phase III, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756-61
   PubMed Web of Science ®Google Scholar
• Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165(5):1585-9
   PubMed Web of Science ®Google Scholar
• Plenaxis (abarelix for injectable suspension). Available from: http://www.fda.gov/cder/drug/infopage/plenaxis/default.htm. [Accessed 3 March 2007]
   Google Scholar
• Goldenberg SL, Bruchovsky N. Use of cyproterone acetate in prostate cancer. Urol Clin North Am 1991;18(1):111-22
   PubMed Web of Science ®Google Scholar
• De Voogt HJ. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer. Prostate Suppl 1992;4:91-5
   PubMedGoogle Scholar
• Iversen P. Antiandrogen monotherapy: indications and results. Urology 2002;60(3 Suppl 1):64-71
   PubMedGoogle Scholar
• De Voogt HJ, Smith PH, Pavone-Macaluso M, De Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135(2):303-7
   PubMedGoogle Scholar
• Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596-605
   PubMed Web of Science ®Google Scholar
• Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51(2):306-14
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33(5):447-56
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164(5):1579-82
   PubMed Web of Science ®Google Scholar
• Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. Eur Urol 1994;26(Suppl 1):10-4
   PubMedGoogle Scholar
• Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17(7):2027-38
   PubMed Web of Science ®Google Scholar
• See WA, Wirth MP, Mcleod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168(2):429-35
   PubMed Web of Science ®Google Scholar
• Iversen P, Johansson JE, Lodding P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004;172(5 Pt 1):1871-6
   PubMed Web of Science ®Google Scholar
• Schellhammer PF. An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opin Pharmacother 2002;3(9):1313-28
   PubMedGoogle Scholar
• Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997;31(1):65-75
   PubMed Web of Science ®Google Scholar
• Mcleod DG, Iversen P. Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 2000;56(5):713-20
   PubMed Web of Science ®Google Scholar
• Delaere KP, Van Thillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 1991;18(5 Suppl 6):13-8
   Google Scholar
• Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996;14(8):2250-7
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996;155(1):209-12
   PubMedGoogle Scholar
• Mcleod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997;2(1):18-27
   PubMedGoogle Scholar
• Sandow J, Von Rechenberg W, Engelbart K. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol 1988;11(Suppl 1):S6-10
   Google Scholar
• Geller J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol 1985;12(1 Suppl 1):28-35
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Giguere M, et al. Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol 1988;61(4):341-6
   PubMedGoogle Scholar
• Huggins C, Scott W. Bilateral adrenalectomy in prostate cancer: clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg 1945;122:1031-41
   Web of Science ®Google Scholar
• Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001;57(4):727-32
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036-42
   PubMed Web of Science ®Google Scholar
• Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92(21):1731-9
   PubMed Web of Science ®Google Scholar
• Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95(2):361-76
   PubMed Web of Science ®Google Scholar
• Group PCTC. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8
   PubMed Web of Science ®Google Scholar
• Klotz L. Combined androgen blockade: an update. Urol Clin North Am 2006;33(2):161-6, v-vi
   PubMedGoogle Scholar
• Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 1997;24(2):421-31
   PubMed Web of Science ®Google Scholar
• Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol 1998;34(Suppl 3):18-23
   PubMedGoogle Scholar
• Shi XB, Ma AH, Xia L, Kung HJ, De Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002;62(5):1496-502
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Rahman M, Takatera H, et al. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002;277(7):4609-17
   PubMedGoogle Scholar
• Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 2003;100(9):5124-9
   PubMedGoogle Scholar
• Rahman MM, Miyamoto H, Takatera H, et al. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem 2003;278(22):19619-26
   PubMedGoogle Scholar
• Lee YF, Lin WJ, Huang J, et al. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 2002;62(21):6039-44
   PubMed Web of Science ®Google Scholar
• Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Ann Rev Biochem 1994;63:25-61
   PubMed Web of Science ®Google Scholar
• Kaplan SA. 5alpha-reductase inhibitors: what role should they play? Urology 2001;58(6 Suppl 1):65-70; discussion 70
   PubMedGoogle Scholar
• Ornstein DK, Smith DS, Andriole GL. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 1998;52(6):1094-7
   PubMed Web of Science ®Google Scholar
• Kirby R, Robertson C, Turkes A, et al. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 1999;40(2):105-14
   PubMedGoogle Scholar
• Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001;6(2):177-82
   PubMed Web of Science ®Google Scholar
• Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 2001;87(1):47-56
   PubMedGoogle Scholar
• Mcleod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247-54
   PubMed Web of Science ®Google Scholar
• Reese DM. Choice of hormonal therapy for prostate cancer. Lancet 2000;355(9214):1474-5
   PubMedGoogle Scholar
• Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51(3):389-96
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. BJU Int 2006;97(3):435-8
   PubMed Web of Science ®Google Scholar
• Iversen P. The third analysis of the bicalutamide Early Prostate Cancer programme. BJU Int 2006;97(3):438-9
   PubMed Web of Science ®Google Scholar
• Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175(1):27-34
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7
   PubMed Web of Science ®Google Scholar
• Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996;58(2):139-46
   PubMed Web of Science ®Google Scholar
• Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am 2006;33(2):167-79, vi
   PubMed Web of Science ®Google Scholar
• Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58(11):2546-50
   PubMed Web of Science ®Google Scholar
• Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized Phase III clinical trial using limited hormonal therapy. J Urol 2005;173(5):1567-71
   PubMedGoogle Scholar
• Youssef E, Tekyi-Mensah S, Hart K, Bolton S, Forman J. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer. Am J Clin Oncol 2003;26(5):e119-23
   Google Scholar
• Prapotnich D, Fizazi K, Escudier B, et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003;43(3):233-9; discussion 239-40
   PubMed Web of Science ®Google Scholar
• De Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163-71
   PubMedGoogle Scholar
• Peyromaure M, Delongchamps NB, Debre B, Zerbib M. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. Urology 2005;65(4):724-9
   PubMedGoogle Scholar
• De La Taille A, Zerbib M, Conquy S, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003;91(1):18-22
   PubMedGoogle Scholar
• Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998;91(9):855-7
   PubMed Web of Science ®Google Scholar
• Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 1994;152(4):1170-3
   PubMed Web of Science ®Google Scholar
• Smith JA Jr. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. J Urol 1994;152(1):132-4
   PubMedGoogle Scholar
• Smith JA Jr. Management of hot flushes due to endocrine therapy for prostate carcinoma. Oncology (Williston Park) 1996;10(9):1319-22; discussion 1324
   PubMedGoogle Scholar
• Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331(6):347-52
   PubMed Web of Science ®Google Scholar
• Langenstroer P, Kramer B, Cutting B, et al. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 2005;174(2):642-5
   PubMed Web of Science ®Google Scholar
• Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 2006;33(2):181-90, vi
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16(7):2377-81
   PubMed Web of Science ®Google Scholar
• Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162(1):98-102
   PubMed Web of Science ®Google Scholar
• Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother 2005;6(7):1095-106
   PubMed Web of Science ®Google Scholar
• Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004;63(4):742-5
   PubMed Web of Science ®Google Scholar
• Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56(6):779-86
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Payne H, Tammela TL, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004;60(2):476-83
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23(4):808-15
   PubMed Web of Science ®Google Scholar
• Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol (2007) 52(1):106-14
   PubMedGoogle Scholar
• Melton LJ III, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol 2003;169(5):1747-50
   PubMed Web of Science ®Google Scholar
• Morote J, Martinez E, Trilla E, et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003;44(6):661-5
   PubMedGoogle Scholar
• Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177(1):17-24
   PubMed Web of Science ®Google Scholar
• Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003;61(1):127-31
   PubMed Web of Science ®Google Scholar
• Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001;28(4 Suppl 11):49-53
   PubMed Web of Science ®Google Scholar
• Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(Suppl 4):28-37
   PubMed Web of Science ®Google Scholar
• Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-7
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):433-41
   PubMed Web of Science ®Google Scholar
• Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343(9):604-10
   PubMed Web of Science ®Google Scholar
• Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345(13):948-55
   PubMed Web of Science ®Google Scholar
• Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008-12
   PubMed Web of Science ®Google Scholar
• Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24(24):3979-83
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365(9468):1415-28
   PubMed Web of Science ®Google Scholar
• Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004;171(6 Pt 1):2285-90
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005;90(2):657-60
   PubMed Web of Science ®Google Scholar
• Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86(9):4261-7
   PubMed Web of Science ®Google Scholar
• Yannucci J, Manola J, Garnick MB, et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006;176(2):520-5
   PubMed Web of Science ®Google Scholar
• Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110(7):1493-500
   PubMed Web of Science ®Google Scholar
• Holzbeierlein JM, Castle EP, Thrasher JB. Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003;2(3):147-52
   PubMedGoogle Scholar
• Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(2 Suppl 1):32-8
   PubMed Web of Science ®Google Scholar
• Information for Healthcare Professionals. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm. [Accessed 3 September 2007]
   Google Scholar
• Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90(4):427-32
   PubMed Web of Science ®Google Scholar
• Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 2004;10(22):7575-82
   PubMed Web of Science ®Google Scholar
• Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006;176(6 Pt 1):2443-7
   PubMed Web of Science ®Google Scholar
• Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 2003;170(5):1808-11
   PubMed Web of Science ®Google Scholar
• Salminen EK, Portin RI, Koskinen AI, Helenius HY, Nurmi MJ. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 2005;103(7):1381-7
   PubMed Web of Science ®Google Scholar
• Gleave ME, Sato N, Goldenberg SL, et al. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. J Urol 1997;157(5):1727-30
   PubMedGoogle Scholar
• Schulman CC, Debruyne FM, Forster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38(6):706-13
   PubMed Web of Science ®Google Scholar
• Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112-6
   PubMed Web of Science ®Google Scholar
• Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int (2002) 90(6):561-6
   PubMed Web of Science ®Google Scholar
• Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170(3):791-4
   PubMed Web of Science ®Google Scholar
• Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166(2):500-6; discussion 506-7
   PubMed Web of Science ®Google Scholar
• Gleave ME, Goldenberg SL, Chin J, Al E. Randomized comparative study of 3 vs. 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 2003:169
   Google Scholar
• Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177(6):2106-31
   PubMed Web of Science ®Google Scholar
• Roach M III, Izaguirre A. Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opin Pharmacother 2007;8(2):257-64
   PubMed Web of Science ®Google Scholar
• Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37(2):247-52
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292(7):821-7
   PubMed Web of Science ®Google Scholar
• Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6(11):841-50
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15(3):1013-21
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 2002;360(9327):103-6
   PubMed Web of Science ®Google Scholar
• Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8
   PubMed Web of Science ®Google Scholar
• Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159(6):2030-4
   PubMedGoogle Scholar
• Bolla M, Artignan X, Fourneret P, et al. Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer. Bull Cancer 2006;93(11):1101-5
   PubMedGoogle Scholar
• Roach M, Lu J, Pilepich MV, Al E. Predicting long term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47:617-27
   PubMed Web of Science ®Google Scholar
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79(2):235-46
   PubMedGoogle Scholar
• Kirk D. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 2000;86(Suppl 3):220
   PubMedGoogle Scholar
• Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006;106(8):1708-14
   PubMed Web of Science ®Google Scholar
• Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002;60(2):201-8
   PubMed Web of Science ®Google Scholar
• Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004;172(5 Pt 1):1865-70
   PubMed Web of Science ®Google Scholar
• Graff JN, Mori M, Li H, et al. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. J Urol 2007;177(4):1307-12
   PubMedGoogle Scholar
• Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84
   PubMed Web of Science ®Google Scholar
• Johansson JE, Adami HO, Andersson SO, et al. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267(16):2191-6
   PubMed Web of Science ®Google Scholar
• Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24(12):1868-76
   PubMedGoogle Scholar
• Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-9
   PubMed Web of Science ®Google Scholar
• Messing E, Manola J, Sarosdy M, et al. Immediate hormonal therapy combined with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer: results at 10 yearst of EST 3886. J Urol 2003;169(Suppl 4):396
   Google Scholar
• Jordan WP Jr, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 1977;70(12):1411-3
   PubMedGoogle Scholar
• Madeb R, Golijanin D, Messing E. Early versus late hormone treatment of metastatic prostate cancer. In: Dawson C, et al., editors. The Evidence for Urology. Barnes, Shrewsbury, UK:Castle Hill; 2004. p. 165-80
   Google Scholar